Deal Terms That Kill Raises: Participating Preferred, Full Ratchet, and the $10M to $100M Exit Mistake

Most founders and sponsors run their exit math at the number that makes the deal look good. A $100M outcome covers almost any term structure. Participating preferred looks reasonable. Full ratchet anti-dilution feels like a formality. The waterfall works. The problem is that institutional allocators do not underwrite to the number that makes the deal look good. They test the $10M to $30M band first, because that is where most exits actually land, and because a term structure that only works at the optimistic case is not a structure at all.

The problem is that institutional allocators do not underwrite to the number that makes the deal look good. They test the $10M to $30M band first, because that is where most exits actually land, and because a term structure that only works at the optimistic case is not a structure at all.

The real raise-killer is not investor downside protection. It is term structures that make a realistic exit unattractive and signal to future capital that alignment was never the priority.

Three things happen when a cap table carries aggressive terms into a new raise:

• Current investors are over-rewarded in ordinary outcomes, leaving founders and sponsors structurally undermotivated
• Incoming investors must underwrite around existing paper before they can evaluate the deal itself
• The term package signals weak negotiating leverage or poor alignment discipline, which allocators read before diligence starts

Running a capital raise audit before going to market often surfaces these structural problems early, when they are still solvable. By the time an allocator flags them in a live process, the damage is already priced in as timeline and credibility loss.

The $10M to $30M Exit Test Is the Only Math That Matters

When an allocator looks at a term sheet, the first question is not "does this work at a great outcome?" It is "does this work at a mediocre one?" A deal that only makes sense at $100M is a deal that requires everything to go right. Most institutional mandates are built around what happens when things go ordinarily.

Here is how a 1x participating preferred with no cap plays out across three exit scenarios, assuming $10M raised at a $30M pre-money valuation with investors holding 25% of the common after conversion:

The $10M exit is the one that reveals the problem. At that number, the investor recovers the full preference and common holders receive nothing. Management, sponsors, and co-investors who hold common are structurally unmotivated at the most likely exit range.

Future investors see this table before they see your pitch deck. If prior paper over-rewards early capital in ordinary outcomes, the next round faces a harder underwriting problem: new money must compensate for the alignment deficit that already exists in the stack.

The $100M scenario is not a lie. It is just not the scenario that determines whether a deal is fundable.

Why Participating Preferred Scares Better Money

Participating preferred is not inherently predatory. In an early-stage deal with genuine binary risk, an investor recovering their preference before sharing in upside is a defensible structure. The problem is context and degree.

When participating preferred shows up in a mainstream institutional round, or in a real estate preferred equity structure where exit values are more predictable, it reads differently. It reads as a signal that the investor did not trust the deal enough to accept standard non-participating terms, and that the sponsor did not have enough leverage to push back.

When Participating Preferred Is Defensible

• Seed or pre-revenue rounds where binary outcomes are real
• Bridge financing with genuine distress risk
• Deals where the investor is providing unusual operational support alongside capital
• Structures with a participation cap (typically 2x to 3x) that limits the double-dip

When Participating Preferred Becomes a Raise-Killer

• Growth-stage rounds where non-participating preferred is the market standard
• Real estate preferred equity where exit ranges are narrow and predictable
• Any structure with uncapped participation, because the math gets worse as the deal gets more successful at ordinary levels
• Rounds where the participation clause sets a precedent the next investor will be asked to match or negotiate around

The deeper issue is what the term says about the next round. Incoming institutional capital is not just evaluating the deal. It is evaluating whether the existing paper leaves room for clean new money. Uncapped participating preferred on prior rounds often forces new investors to negotiate a restructure before they can commit, which adds months to a 4 to 9 month raise timeline and sometimes kills the round entirely.

Why Full Ratchet Anti-Dilution Is Usually a Distress Signal

Anti-dilution protection exists for a legitimate reason: investors who commit capital at a given valuation should not be structurally punished if a later round prices lower. The question is how aggressively that protection is written, and what it signals about the deal's expected trajectory.

There are two main anti-dilution mechanisms. Weighted average adjusts the conversion price based on the size and price of the down round, which softens the impact proportionally. Full ratchet resets the conversion price to the new lower price entirely, as if every prior dollar had invested at the worst price. The difference in ownership impact can be significant.

Before and After a Down Round: Weighted Average vs. Full Ratchet

Assume an investor puts in $5M at $1.00 per share, receiving 5 million shares. A subsequent round prices at $0.50 per share.

The full ratchet scenario doubles the investor's share count without any additional capital. Every other shareholder, including the new round's investors, absorbs that dilution.

Sophisticated allocators read full ratchet as a distress signal, not a negotiating win. It tells them the prior round expected weak pricing support, or that the sponsor had no leverage to negotiate a market-standard weighted average clause. Either reading reduces confidence in the deal's trajectory.

The clause does not even need to be triggered to cause damage. Incoming investors know that a full ratchet sitting on the cap table is a loaded mechanism. If the next round prices lower, the ownership math becomes unpredictable. That uncertainty gets priced into the terms new investors demand, or it becomes the reason they pass entirely.

Weighted average anti-dilution, by contrast, is standard in institutional rounds and rarely draws scrutiny. The presence of full ratchet, in a growth-stage or institutional context, is almost always worth flagging before a new raise opens.

What Institutional Allocators Infer From These Terms

Allocators are not reading your term sheet to understand your history. They are reading it to decide whether you understand alignment. The terms you accepted in a prior round are evidence of how you negotiate, how you think about future capital, and whether you optimized for closing quickly over building a financeable structure.

When an allocator sees aggressive terms in the existing cap table, they typically draw one of three inferences:

1. Weak negotiating position. The sponsor or founder accepted terms they could have pushed back on, which raises questions about leverage in future negotiations, including with the allocator now reviewing the deal.
2. Poor alignment discipline. A management team that accepted uncapped participating preferred or full ratchet without a fight is a team that may not fully understand how those terms affect future rounds, or did not prioritize the long-term capital stack over the immediate close.
3. Optimizing for close over financeability. Taking whatever terms were offered to get the round done is understandable under pressure, but it is a signal that future capital events may be managed the same way. Institutional allocators building long-term positions do not want to be the next round that gets restructured around.

None of these inferences are moral judgments. They are underwriting inputs. The question an allocator is asking is not "were these terms fair?" It is "can I underwrite a clean position into this stack, and will this team make decisions that protect my capital's long-term position?"

If the answer to either question is uncertain, the deal gets slower. Mandate alignment becomes harder when the cap table itself is a variable that needs solving before the deal can be evaluated on its merits. That is why mandate alignment is evaluated alongside term structure, not after it.

{{main-cta}}

How to Pressure-Test Terms Before You Go Back to Market

Before opening a new raise, every term in the existing cap table should pass three screens. These are not negotiation tactics. They are diagnostic filters that tell you whether the current structure is fundable at all.

The Three-Screen Term Audit

1. Realistic exit math. Model the $10M, $20M, and $30M outcomes before the $100M one. If common holders or management receive nothing meaningful below $30M, the structure has an alignment problem that future investors will price in.
2. Future round survivability. Ask whether a new institutional investor can take a clean position without first negotiating around existing paper. If the answer requires a cap table restructure, the raise timeline extends by months and the deal loses credibility with allocators who move on quickly.
3. Mandate fit signal. Consider what the term package communicates to the type of capital you want next. Institutional allocators running a 12-category screening process read term structure as an alignment signal before they read the deck. Terms that worked for a bridge lender may disqualify you with a family office or growth equity fund.

The Capital Raise Pre-Flight diagnostic runs all 12 categories, including term structure and cap table alignment, and returns a scored 0 to 100 readiness assessment in 10 business days. Deals scoring below 85 typically surface at least one structural issue that would slow or stop a live raise.

Term structure is one gate. The others matter equally. Understanding whether a pass or not-yet verdict is coming before you go to market is the difference between a 4 to 9 month raise and one that never closes.

‍

Frequently Asked Questions

‍

Does participating preferred automatically kill a future raise?

Participating preferred does not automatically kill a raise, but uncapped participating preferred on prior rounds adds friction to every subsequent one. Institutional allocators need to underwrite around existing paper before they can evaluate new money, and that process can add 60 to 90 days to a raise that was already 4 to 9 months long. Whether it kills the deal depends on the exit math at realistic values, not the optimistic case.

What is the difference between full ratchet and weighted average anti-dilution?

Full ratchet resets the conversion price of prior shares to the new lower price entirely, regardless of round size, which can double or triple prior investors' share counts after a single down round. Weighted average adjusts the conversion price proportionally based on the size and price of the down round, producing a more moderate ownership shift. Institutional allocators treat weighted average as standard and full ratchet as a distress signal.

At what exit value does participating preferred become a structural problem?

Participating preferred typically becomes a structural problem below the 3x return threshold on invested capital. In a deal with $10M raised on 1x participating preferred, any exit below roughly $30M leaves common holders competing with the preference recovery plus participation, which can reduce or eliminate their proceeds. The $10M to $30M exit band is where most deals actually land, making this the critical test range.

Can bad deal terms from a prior round be fixed before a new raise?

Yes, prior terms can be amended, but the process requires existing investor consent and often involves economic trade-offs. Common remedies include converting participating preferred to non-participating, adding or lowering a participation cap, or replacing full ratchet with weighted average anti-dilution. Each amendment negotiation adds time and signals to incoming investors that the cap table required repair, which is its own due diligence flag.

How do institutional allocators screen for term structure problems?

Most institutional allocators review the cap table and prior term sheets as part of a structured diligence process that covers 12 or more screening categories. Term structure is evaluated alongside mandate alignment, financial model quality, and management track record. A deal that passes on fundamentals but carries aggressive prior paper often receives a not-yet verdict rather than a pass, with the expectation that the structure gets cleaned up before re-engagement.

Does an Institutional Readiness Score account for cap table and term structure?

Yes. A readiness score built across 12 categories includes cap table structure, liquidation preference mechanics, and anti-dilution provisions as scored inputs. Deals scoring below 85 on a 0 to 100 scale typically carry at least one structural issue in these categories. The score is not a prediction of investor interest; it is a diagnostic of whether the deal is structurally ready to enter a live raise without avoidable friction.

How long does it take to get a term structure assessment before going to market?

A structured pre-raise diagnostic covering term structure, cap table alignment, and 10 other institutional readiness categories takes 10 business days and produces a 20 to 30 page report scored from 0 to 100. That report gives sponsors and founders a clear picture of which structural issues will surface in live diligence before they spend months in a raise that stalls on solvable problems.

‍

‍

Continue reading this series:

• 12-category pass/fail diagnostic
• pitch deck audit
• capital raise audit